

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-10** | Period of Report: **2013-01-06**
SEC Accession No. [0001415889-13-000043](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

VistaGen Therapeutics, Inc.

CIK: **1411685** | IRS No.: **205093315** | State of Incorpor.: **NV** | Fiscal Year End: **0331**
Type: **8-K** | Act: **34** | File No.: **000-54014** | Film No.: **13523064**
SIC: **2834** Pharmaceutical preparations

Mailing Address

384 OYSTER POINT
BOULEVARD, NO. 8
SOUTH SAN FRANCISCO CA
94080

Business Address

384 OYSTER POINT
BOULEVARD, NO. 8
SOUTH SAN FRANCISCO CA
94080
650-244-9997 X224

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 6, 2013

Commission File Number: 000-54014

VistaGen Therapeutics, Inc.

(Exact name of small business issuer as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

205093315

(IRS Employer Identification No.)

384 Oyster Point Blvd, No. 8, South San Francisco, California 94080

(Address of principal executive offices)

650-244-9990

(Registrant's Telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective January 6, 2013, Gregory A. Bonfiglio, a member of the Company's Board of Directors since 2007, resigned from his position as a Director and member of the Audit Committee to perform his new full-time responsibilities as managing principal of a recently-formed, privately-held hedge fund.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: *January 10, 2013*

By: */s/ Shawn K. Singh*

Name: Shawn K. Singh

Title: Chief Executive Officer